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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Antidepressant use has increased in the last
decade. Several studies have suggested a
possible association between maternal
antidepressant use and teratogenic effects.
In a review of the pharmacologic literature
we showed that antidepressant exposure
might disturb the development of the
enteric nervous system.
WHAT THIS STUDY ADDS
• In utero exposure to selective serotonin
re-uptake inhibitors (SSRIs) in the second
and third trimester or to tricyclic antidepres-
sants (TCAs) in the first trimester leads to a
significant increase in laxative use compared
with non-exposed children. SSRI exposure
was not associated with significant increased
antidiarrhoeal medication use, but TCA
exposure was.
AIMS
Antidepressant use has increased in the last decade. Several studies have suggested a
possible association between maternal antidepressant use and teratogenic effects.
METHODS
The pharmacy prescription database IADB.nl was used for a cohort study in which
laxative and antidiarrhoeal medication use in children after in utero exposure to
antidepressants (TCA, SSRI, fluoxetine or paroxetine exposed) was compared with no
antidepressant exposure. Laxatives and antidiarrhoeal medication use were applied
as a proxy for constipation and diarrhoea respectively, which may be associated with
disturbed enteric nervous system (ENS) development.
RESULTS
Children exposed in utero to SSRIs (mainly fluoxetine and paroxetine) in the second
and third trimester or to TCAs in the first trimester, more often received laxatives.
Combined exposure to TCAs and SSRIs in pregnancy was associated with a 10-fold
increase in laxative use. In utero exposure to SSRIs is not associated with
antidiarrhoeal medication use compared with non-exposed children. In contrast,
antidiarrhoeal medication use was significantly higher in children exposed to TCAs
anytime in pregnancy.
CONCLUSIONS
The increased laxative use after second and third trimester exposure to SSRIs might be
explained through the inhibitory effect of the serotonin re-uptake transporter (SERT)
and because of selectivity for the 5-HT2B receptor which affects the ENS.TCA exposure
during the first trimester leads to increased laxative use probably through inhibition of
the norepinephrine transporter (NET). Exposure of TCAs anytime in pregnancy leads to
increase diarrhoeal use possibly through down-regulation of a2-adrenoceptors or
up-regulation of the pore forming a1c subunit.
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Introduction
Antidepressant use has increased during the last decade
[1, 2]. Women are advised to step down pharmacotherapy
before conception and to switch to, for example, psycho-
therapy [3–10]. The use of selective serotonin re-uptake
inhibitors (SSRIs) especially during pregnancy seems not
to be evidence based [11].
Several studies have suggested a possible association
between maternal antidepressant use and teratogenic
effects, but these studies are frequently complicated by
methodological issues. Studies about the teratogenic risk
of maternal tricyclic antidepressant (TCA) use present con-
tradictory results. A Swedish study found an increased risk
of heart defects after maternal clomipramine use [12],
while other studies have found no teratogenic effects after
TCA use during pregnancy or before conception [13–16].
Several cohort studies that examined the use of SSRIs in
pregnancy found no increased risk of major congenital
anomalies [17–21], while other cohort studies have
reported an association between SSRI use and adverse
pregnancy outcomes such as low birth weight, short ges-
tational age and an increased prevalence of minor con-
genital anomalies [18, 22]. Paroxetine is associated with an
increased risk for cardiac anomalies and pulmonary hyper-
tension. Therefore paroxetine is contra-indicated just prior
to conception and during pregnancy [23–31]. In addition,
an association between maternal use of fluoxetine and
infantile hypertrophic pyloric stenosis (IHPS) was reported
[32]. However many studies have reported no teratogenic
effects for TCAs, SSRIs or any other antidepressant [19–21,
26, 33–37], although the statistical power of published
studies is low [38].
There were no case reports or studies found reporting
disturbed bowel function when exposed to antidepres-
sants in utero. The previously conducted pharmacological
literature study [39] showed that SSRIs could influence the
development of the enteric nervous system (ENS) in two
ways: (i) through inhibition of the serotonin re-uptake
transporter (SERT) and (ii) through binding of some SSRIs
(fluoxetine and paroxetine) to the 5-HT2B receptor. Since
the SERT plays a role in the development of the ENS by
regulating the 5-HT concentrations, blockage of these
transporters during fetal development could influence
migration, differentiation and survival of cells. This could
lead to abnormal development in the first trimester of
pregnancy. The 5-HT2B receptor mediates the growth
factor-like action of 5-HT on developing enteric neurons. It
is possible that stimulation of 5-HT2B receptors by 5-HT
influences the fates of late-developing enteric neurons
and new neurons continue to be added to the ENS for at
least 3 weeks postnatally in mice.These observations could
lead to abnormal development in the second and third
trimester. TCAs could influence the development of the
ENS through inhibition of the norepinephrine transporter
(NET). Expression of the NET seems to be essential for a full
development of enteric neurons and especially for sero-
tonergic neurons. Since the NET is detected early in ontog-
eny and precedes neuronal differentiation, this suggests
that TCAs might influence development of the ENS when
exposed early in pregnancy. In summary it might be
expected based on this review of the pharmacologic litera-
ture [39] that: (i) in utero exposure to SSRIs in the first tri-
mester,but also the second and the third trimester will lead
to disturbed bowel function and (ii) in utero exposure to
TCAs in especially the first trimester will lead to disturbed
bowel function.
The aim of this cohort study is to explore the use of
laxatives and antidiarrhoeal medication as proxy for con-
stipation and diarrhoea respectively, in childhood after
SSRI and TCA exposure in utero. With this study we intend
to demonstrate that medication use in childhood can be
used as a proxy for minor birth defects due to medication
exposure in pregnancy.
Methods
This study was performed with IADB.nl, which contains
pharmacy prescription data of an estimated population of
500 000 individuals from the Netherlands. Registration in
the database is irrespective of health insurance and is con-
sidered representative for the general population. Each
prescription record contains information on the date of
dispensing, the quantity dispensed, the dose regimen, the
number of days the prescription is valid, the prescribing
physician and the Anatomical Therapeutic Chemical code
(ATC code). Each patient has a unique anonymous identi-
fier; date of birth and gender are known. Due to the high
patient-pharmacy commitment in the Netherlands, the
medication records for each patient are virtually complete
[40], except for over the counter (OTC) drugs and medica-
tion dispensed during hospitalization.
The data for this study were obtained from the ‘Preg-
nancy IADB’,which was extracted from the main IADB data-
base. Children were selected by date of birth and the
female person (15–50 years) with the same address code
was considered to be the mother [41]. Because only the
child’s birth date is known, the theoretical conception date
was determined as the date of birth minus 273 days (i.e.
9 months). The database has been previously described
[1, 42].
The data between 1995 and 2009 from the pregnancy
database were used. Focusing on our study objective; we
determined the relative risk for laxative and antidiarrhoeal
medication use in children after in utero antidepressant
exposure.
Study population, exposure and
reference groups
We identified in the period 1995–2009, 35 400 pregnancies
occurring to 24 467 women. From these 35 400 pregnan-
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cies 36 323 children were born. The exposure to antide-
pressants was calculated during the three trimesters of
pregnancy of each woman. Exposure was defined as the
theoretical period of use, from dispensing date until the
last day the prescription was valid. Two exposure groups
were formed i.e. children of mothers exposed to tricyclic
antidepressants (TCAs; ATC code = N06AA) and children of
mothers exposed to selective serotonin re-uptake inhibi-
tors (SSRIs; ATC code = N06AB) during pregnancy. In addi-
tion we analyzed a group who was exposed to both a SSRI
and a TCA (ATC code = N06AA and N06AB). These cases
were excluded from the TCA exposed group and SSRI
exposed group. All prescriptions of TCAs with less than 0.5
defined daily doses (DDDs) per day were excluded,
because TCAs are used for treating neuropathic pain in a
lower dose than for treating depression.
In the SSRI exposure group we performed sub-
analyses for fluoxetine (ATC code = N06AB03) and for par-
oxetine (ATC code = N06AB05). The time of exposure to
antidepressants was divided into the following periods:
the whole pregnancy, only the first trimester, only the
second and third trimester combined, at least the first
trimester and at least the second and third trimester
combined.
The reference group consisted of women who did not
use any SSRIs or TCAs during pregnancy and during a
period of 7 days before pregnancy.
Laxative and antidiarrhoeal medication use
(proxy drugs)
The use of laxatives (ATC code = A06) and antidiarrhoeal
medication (ATC code = A07C; A07D; A07F; A07X) in the
newborn was studied in the exposed groups and the ref-
erence group,and was regarded as a proxy for constipation
and diarrhoea, respectively. Laxative and anti-diarrhoeal
medication use was defined as the starting date of a pre-
scription for these medications.
Analysis
The calculated day of conception was chosen as the start-
ing point to identify in which periods the children were
exposed.The day of birth of the children was chosen as the
starting point for the follow-up. The incidence rate (IR) of
laxative use and of antidiarrhoeal medication use in the
defined exposure groups was calculated as the number of
incident cases (laxative or antidiarrhoeal users) divided by
the time at risk (in years) [43]. The use was studied in the
first 5 years of the life of a child. The time at risk was mea-
sured from the day of birth until either the first prescription
date, the last known date of the child in the database or the
end of the study period, whichever occurred first. The
exposure groups and reference group were compared and
the incidence risk ratio (IRR) and 95% confidence interval
(CI) were calculated [43].
Results
Laxatives as proxy for constipation
From the 35 400 pregnancies in our population, 36 323
children were born. Exposure to an SSRI anytime in preg-
nancy occurred in 512 pregnancies and 527 children. Par-
oxetine was the most commonly prescribed SSRI (n =
310), followed by fluoxetine (n = 105), citalopram (n = 60),
fluvoxamine (n = 60), sertraline (n = 19) and escitalopram
(n = 2). Exposure to a TCA anytime in pregnancy occurred
in 72 pregnancies and to 76 children. The most com-
monly used TCA was clomipramine (n = 40), followed by
amitriptyline (n = 26). One woman used three different
TCAs during pregnancy. In the period 1995–2009 34 908
children (34 022 pregnancies) were not exposed to any
medication.
Table 1 presents the use of laxatives estimated as inci-
dence in the reference group and the different exposure
groups (SSRIs, TCA, fluoxetine and paroxetine) as well as
the different periods of exposure (anytime, only first tri-
mester, only second and third trimester, at least first trimes-
ter and at least second and third trimester).The number of
incident cases (antidiarrhoeal medication and laxative
users) and the time at risk were used to calculate the IR.
SSRI exposure anytime in pregnancy was related to a sig-
nificant increase in laxative use in the child (IRR = 1.37, 95%
IRR 1.11, 1.68). Especially exposure in the secod and third
trimester seems to be related to an increased use of laxa-
tive. At least exposed in the second and third trimester
compared with non-exposed is related to an IRR of 1.68
(95% IRR 1.30, 2.18).
In contrast exposure to TCAs shows a significant
increase in laxative use of the child when the mother is
exposed only in the first trimester (IRR = 1.94, 95% IRR 1.05,
3.62).There was no significant increase seen when exposed
to a TCA anytime in pregnancy and the other defined
exposure times.
The IRRs of fluoxetine and paroxetine exposure are pre-
sented separately. Fluoxetine exposure was related to a
higher use of laxatives in the child when exposed only in the
ssecond and third trimester (IRR = 2.51, 95% IRR 1.05, 5.05)
and borderline significant in the category at least the
second and third trimester exposure (IRR = 1.70, 95% IRR
0.99, 2.93). In the paroxetine exposed group a significant
increase in laxative use is seen when exposed anytime in
pregnancy (IRR= 1.35,95% IRR 1.03,1.78),at least in the first
trimester (IRR = 1.41, 95% IRR 1,06, 1.88) and at least in the
second and third trimester (IRR = 1.72, 95% IRR 1.22, 2.42).
There were 12 pregnancies in which the child was
exposed to a TCA and a SSRI in succession. Due to low
numbers the IRR was only calculated for exposure anytime
in the pregnancy. Exposure to both a TCA and a SSRI com-
pared with non-exposed was related to an IRR of 9.64 (95%
IRR 4.82, 19.28).
During the study period 1995–2009 lactulose (n = 3378)
was the most commonly prescribed laxative, followed by
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macrogol (n= 509), liquid paraffin (n= 354) and bisacodyl (n
= 265). The pattern of starting laxative use after in utero
exposure to SSRIs or TCAs is presented in Figure 1. In almost
all exposure categories most children started using
laxatives in the first 6 months after birth except for the TCA
group where the peak was between 6 months to 1 year and
between 2.5–4.5 years after birth. However this could be
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Figure 1
The use of laxatives after in utero exposure to SSRIs or TCAs compared with no medicine exposure.The y-axis describes the percentage starting laxatives and
the x-axis the time period in which they started using laxatives in years. Fluoxetine ( ); Paroxetine ( ); SSRI ( ); TCA ( ); Reference ( )
Table 1
The use of laxatives after in utero exposure to SSRIs or TCAs
Laxatives
Group Pregnancy period Children Laxative users Time at risk (years) IR (years) IRR (95% CI)
Reference
Anytime 34 908 4847 119 612 0.0405 1
SSRI exposed
Anytime 527 89 1611 0.0552 1.37 (1.11, 1.68)
Only first trimester 228 31 759 0.0408 1.01 (0.71, 1.68)
Only second and third trimester 54 10 173 0.0577 1.42 (0.77, 2.65)
At least first trimester 473 79 1438 0.0549 1.36 (1.09, 1.70)
At least second and third trimester 299 58 852 0.0681 1.68 (1.30, 2.18)
TCA exposed
Anytime 76 13 271 0.0479 1.18 (0.69, 2.04)
Only first trimester 36 10 127 0.0788 1.94 (1.05, 3.62)
Only second and third trimester 10 0 – – –
At least first trimester 66 13 229 0.0567 1.40 (0.81, 2.41)
At least second and third trimester 40 3 144 0.0208 0.51 (0.17, 1.59)
Fluoxetine
Anytime 105 18 317 0.0569 1.40 (0.88, 2.23)
Only first trimester 36 5 128 0.0391 0.96 (0.40, 2.32)
Only second and third trimester 18 5 49 0.1020 2.51 (1.05, 6.05)
At least first trimester 87 13 268 0.0486 1.20 (0.70, 2.07)
At least second and third trimester 69 13 189 0.0689 1.70 (0.99, 2.93)
Paroxetine
Anytime 301 52 950 0.0547 1.35 (1.03, 1.78)
Only first trimester 138 19 477 0.0398 0.98 (0.63, 1.54)
Only second and third trimester 32 4 111 0.0360 0.89 (0.33, 2.37)
At least first trimester 269 48 839 0.0572 1.41 (1.06, 1.88)
At least second and third trimester 163 33 473 0.0698 1.72 (1.22, 2.42)
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Antidiarrhoeal medication as proxy
for diarrhoea
In addition to the laxatives, we also studied antidiarrhoeal
medication use related to the use of antidepressants by
the mother during pregnancy (Table 2). No increase in
antidiarrhoeal medication use in the child was seen after
exposure to SSRIs in utero. In contrast, exposure to TCAs in
all pregnancy periods, including the first trimester, seemed
to be related to a higher use of antidiarrhoeal medication
in the child compared with the not exposed group. In the
fluoxetine and paroxetine groups no increase in antidiar-
rhoeal medication use was seen (data not shown).
During the period 1995–2009 oral rehydration salt for-
mulas (n = 1330) were the most commonly used antidiar-
rhoeal medication, followed by loperamide (n = 192).
The time after birth when the children were prescribed
an antidiarrhoeal medication was similar for the exposed
and the reference groups (Figure 2).
Discussion
This study shows that the use of SSRIs and TCAs in preg-
nancy increased laxative use in new born children com-
pared with non-exposed children. Children exposed to
SSRIs (mainly fluoxetine and paroxetine) in the second and
third trimester or to TCAs in the first trimester, more often
received laxatives. Combined exposure to TCAs and SSRIs
in pregnancy was associated with a 10-fold increase in
laxative use. Exposure to SSRIs in utero was not associated
Table 2
Antidiarrhoeal medication use after in utero exposure of SSRIs or TCAs
Antidiarrhoeal medication Antidiarrhoeal
med usersGroup Pregnancy period Children Time at risk (years) IR (years) IRR (95% CI)
Reference
Anytime 34 908 1458 12 7471 0.0114 1
SSRI exposed
Anytime 527 18 1 747 0.0103 0.90 (0.57, 1.43)
Only first trimester 228 8 811 0.0099 0.86 (0.43, 1.73)
Only second and third trimester 54 2 188 0.0107 0.93 (0.23, 3.73)
At least first trimester 473 16 1 559 0.0103 0.90 (0.55, 1.47)
At least second and third trimester 299 10 936 0.0107 0.93 (0.50, 1.74)
TCA exposed
Anytime 76 9 268 0.0336 2.94 (1.52, 5.66)
Only first trimester 36 5 135 0.0372 3.26 (1.35, 7.83)
Only second and third trimester 10 1 37 0.0268 2.35 (0.33, 16.67)
At least first trimester 66 8 230 0.0347 3.03 (1.51, 6.08)
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Figure 2
The use of antidiarrhoeal medication after in utero exposure of SSRIs or TCAs compared with no medicine exposure. The y-axis describes the percentage of
starting laxative and the x-axis the time period in which they start using laxatives in years. SSRI ( ); TCA ( ); Reference ( )
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with antidiarrhoeal medication use in these children com-
pared with non-exposed children. In contrast, antidiar-
rhoeal medication use was significantly higher in children
exposed to TCAs anytime in pregnancy. So far there is no
literature available for comparison with the outcome of
this study. In a pharmacologic literature study [39] per-
formed prior to this study we did find indications that
exposure to SSRIs and TCAs during pregnancy may be
associated with a disturbed development of the ENS.
Selective serotonin re-uptake inhibitors
How can we explain the increased use of laxatives in chil-
dren exposed to SSRIs during the second and third trimes-
ter but not during the first trimester? This might be due to
the fact that 5-HT is not only a neurotransmitter but also a
growth factor in the primitive ENS that effects the devel-
opment of late-arising enteric neurons predominantly by
activation of the 5-HT2B receptor [44], which could influ-
ence the development of the late-arising neurons.
The results with respect to paroxetine showed the
same increase in laxative use as SSRIs as a group. However
fluoxetine showed a more than two-fold increase when
used only in the second and third trimester. Does this indi-
cate that fluoxetine might influence the serotonergic path-
ways in a different way from paroxetine and the other
SSRIs? In the literature review we found that fluoxetine and
paroxetine are the only SSRIs that are known to bind to the
5-HT2B receptor, although the selectivity of fluoxetine for
this receptor is higher [39]. Since the development of
enteric neurons through stimulation of the 5-HT2B receptor
persists for a long time and even after birth, a higher selec-
tivity for this receptor might lead to more damage later in
pregnancy. This could explain the increased laxative use
after fluoxetine exposure during the second and third
trimester.
SSRI exposure in all pregnancy periods showed no
increase in antidiarrhoeal medication use. SSRIs may not
affect the pathways in foetal development that cause diar-
rhoea. The body may have mechanisms that compensate
for the 5-HT concentration changes caused by SSRIs.
Tricyclic antidepressants
Can we also explain the increase in laxative use when
exposed exclusively in the first trimester to TCAs? NET is
essential for the development of enteric neurons and par-
ticularly affects serotonergic neurons [45, 46]. Serotonergic
neurons develop early in ontogeny [47, 48], which indi-
cates that defects would occur when exposed in early
pregnancy. Other arguments that solidify the result that
TCAs influence early development of the ENS are that NET
is expressed before neuronal differentiation [46] and that
expression during sympathic neuronal development has
been linked to acquisition of the noradrenergic phenotype
[45].
When exposed to both SSRIs and TCAs in pregnancy
the mechanisms of the antidepressants might amplify
each other.This might explain the high increase in laxative
use that was seen in our results.
In addition to the increase in laxative use, how do we
explain the increase in antidiarrhoeal medication use
when exposed to TCAs even though this is not seen when
exposed to SSRIs? TCAs also influence noradrenergic
pathways and SSRIs do not. It is known that adrenergic
receptors are involved in control of intestinal motility:
stimulation of intestinal a1-, a2- and b2-adrenoceptors
relaxes the smooth muscles in the GI tract, thus slowing
down the peristalsis [49, 50] and a2-adrenoceptor agonists
prevent diarrhoea [51–53]. Due to the TCA induced NE
increase, the presynaptic a2-adrenoceptor and postsynap-
tic b- and a1-receptor desensitize and down-regulate.
Down-regulation of a-adrenoceptors leads to a less effi-
cient adrenergic system which causes increased peristalsis,
electrolyte secretion and decreased absorption, which all
increase the risk of diarrhoea [51, 52]. Administration of
an antagonist can also lead to up regulation of the
a1-adrenoceptor. Due to the up-regulation the receptors
can have a higher response to neurotransmitters.
Enhanced expression of the a1c subunit results in smooth
muscle hyper-reactivity to acetylcholine (ACh), accelerated
colonic transit and increase in defaecation rate [54].
Normal concentrations of NE could have the same effect
on up-regulated a1-adrenoceptors as an increased con-
centration of NE in a normal situation. Down- and
up-regulation can happen anytime in pregnancy which
could be an explanation for the increase in antidiarrhoeal
use through affecting the noradrenergic pathways.
Antidepressants compared
Since SSRIs and TCAs both increase laxative use, although
through exposure in different trimesters, is it possible that
the influence of TCAs on serotonergic pathways causes this
increase? 5-HT as a neurotransmitter is involved in the
motility of the gut. If serotonergic neurons are lost, normal
intestinal motility is diminished (or absent) and transit
down the bowel is slowed [55]. Since we have shown that
SSRI and TCA exposure influences the development of
enteric serotonergic neurons,motility can be diminished in
these children. Consequently this leads to slow transit
down the bowel and the solution can be laxative use. So it
is possible that the serotonergic characteristics of antide-
pressants cause the increase in laxative use.
Limitations
There are some limitations in using an administrative pre-
scription database because we do not know whether the
drugs were actually taken. If the women were not compli-
ant, our results would be an underestimation of the real
effect. In addition our method provides no indication of
how much of the medication was actually taken or com-
pliance in general. Another limitation is that OTC drugs are
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missing. If the children got their laxatives or antidiarrhoeal
as OTC drugs this would also lead to an underestimation of
the effect.
SSRIs and TCAs are prescribed for treating depression,
but also for treating anxiety and personality disorders.
Perhaps these diseases themselves can cause constipation
or diarrhoea by behavioural changes in the mothers. We
have no information about the indication for the pre-
scribed drugs and, therefore, confounding by indication is
still possible. Only randomized controlled follow-up
studies could prevent this form of confounding. De-
pression, in general, in The Netherlands is not related to
socio-economic status. However, confounding due to
socioeconomic factors such as dietary habits leading
to constipation or an increased incidence of infective diar-
rhoea is possible and warrants further investigation.
Oral rehydration salt formulas are the first choice
therapy to treat dehydration from diarrhoea, but also from
other causes which do not represent disturbed ENS devel-
opment. The use of laxatives and antidiarrhoeal medica-
tion as a proxy for disturbed ENS development may not be
an accurate proxy, because they could be used to treat
other diseases and this could lead to confounding.
TCAs and SSRIs also bind to receptors that were not
investigated (muscarine M3-receptor, histamine H1-
receptor), but it is unclear what the function of these
receptors is in the ontogeny of the ENS. The diversity and
numbers of explanations for the results obtained in this
study show the complexity of the development of the ENS.
More research needs to be done to elucidate fully the role
of antidepressants in the development of the ENS.
In conclusion children who were exposed to SSRIs in the
second and third trimester or to TCAs in the first trimester
more often received laxatives. A 10-fold increase in laxative
use was found when exposed to both a SSRI and a TCA
during pregnancy. SSRI exposure in utero was not associ-
ated with antidiarrhoeal medication use in these children,
but TCA exposure anytime in pregnancy was.There were no
case reports or studies found reporting these associations.
The increased laxative use after second and third trimester
exposure to SSRIs might be explained through the inhibi-
tory effect of the SERT and because of selectivity for the
5-HT2B receptor which affects the ENS.TCA exposure during
the first trimester leads to increased laxative use probably
through inhibition of the NET. Exposure of TCAs anytime in
pregnancy may lead to increase diarrhoeal use possibly
through down-regulation of a2-adrenoceptors or up-
regulation of the pore forming a1c subunit.
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